EICHORCondition: Painful Diabetic Peripheral Neuropathy · Sponsor: JAWAD AHMAD ABU-SHENNAR
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Background: Painful diabetic peripheral neuropathy (PDPN) is a severe, disabling complication of type 2 diabetes mellitus (T2DM), closely associated with insulin resistance, chronic neuroinflammation, and oxidative stress. Plant-based dietary supplements, particularly Ceylon cinnamon (Cinnamomum verum), contain bioactive compounds with potential anti-diabetic, antioxidant, and neuroprotective properties. Aim: To evaluate the effects of Ceylon Cinnamon (Cinnamomum verum) supplementation on blood glucose, lipid profile levels, body mass index (BMI), and pain intensity among adult individuals with painful diabetic peripheral neuropathy (PDPN). Methods: A prospective, double-blind, randomized controlled trial (Double-Blind RCT) was conducted (Feb-July 2026) across endocrinology outpatient clinics in Jordan. Participants were randomly allocated in a 1:1 ratio to either the Intervention Group (n = 62; 500 mg Ceylon cinnamon twice daily for 6 months alongside standard care) or the Placebo Control Group (n = 62; 500 mg placebo capsules twice daily for 6 months alongside standard care). Clinical, biochemical, and pain assessments (using the Numeric Rating Scale \[NRS\]) were evaluated at baseline, 3 months, and 6 months post-intervention.
This description comes directly from the study's public registry record.
Dr. Jawad AHMAD ABU-SHENNAR, Asst.Prof.Dr · +962779084560 · JAWAD_0799@YAHOO.COM
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age ≥ 18years diagnosed with PDPN * With documented T2DM Exclusion Criteria: * If they had coexisting chronic conditions, including chronic kidney disease (CKD), hypertension, cardiovascular disease (CVD), or cognitive/sensory impairments (e.g., reading or hearing difficulties). * individuals receiving medications that could confound blood glucose control or pain perception (such as systemic glucocorticoids, weight-loss agents, or iron and vitamin B12 supplements)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Ministry of Health Primary Healthcare Centers | Amman, Jordan | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07743073